Corona Remedies IPO fully subscribed on day 2: Issue booked over 9x; check category-wise status

Until 5 PM, the issue has received bids for 426,666,148 shares compared to 4,571,882 shares on offer, according to the NSE data.

• Qualified Institutional Buyers (QIBs): 1.67x

• Non-institutional Investors: 26.80x

• Retail Individual Investors (RIIs): 6.37x

The minimum lot size for an application is 14 shares, and the investor would have to apply for a minimum of one lot. It is a book-building issue, comprising an offer for sale of ₹655.37 crore.

The IPO comprises an offer for sale (OFS) and carries a price band of ₹1,008–₹1,062 per share. Investors can place their bids at any price within this range when applying for the issue.

Corona Remedies IPO Objective

The money raised from the IPO will be used towards the following objectives:

Corona Remedies IPO date

After closing on December 10, investors are expected to be updated about the allotment status on December 11, 2025. 

Further, the shares of the firm will be listed on the NSE and the BSE on Monday, December 15, 2025.

About the company

Corona Remedies Limited is an India-focused pharmaceutical formulation company that develops, manufactures and markets a wide range of medicines related to women's healthcare, heart and diabetes care, pain relief, urology, and more.

The company offers a diverse portfolio of 71 brands, with 27 of them contributing over 72% of its domestic MAT sales as of June 30, 2025. It operates two manufacturing facilities in Gujarat and Himachal Pradesh, with a combined installed capacity of 128.54 crore units per annum across 11 production lines.

Corona Remedies IPO GMP

According to investorgain.com and media reports, Corona Remedies’ unlisted shares are trading at ₹1,062.64 per share, reflecting a grey market premium (GMP) of 24.2% over the upper price band of ₹1,062.

Disclaimer: Grey Market Premium (GMP) is an unofficial indicator of market sentiment toward an IPO. It is not regulated by the stock exchanges or SEBI. Upstox does not endorse or facilitate trading in the grey market. Investors are advised to conduct their own research or consult an expert before making any investment decisions.